Canterbury DHB

Context

Management

In This Section

Localised cGvHD

1st line therapy of cGvHD

2nd line and beyond therapy of chronic GvHD

Results of an EBMT survey on 1st and 2nd line therapy of chronic GvHD

Localised cGvHD

This typically involves the skin, mouth or eyes.

Significant involvement of other organs, e.g. liver or lungs, is usually seen in association with extensive cGvHD.

1st line therapy of cGvHD

Corticosteroids are the recommended 1st line treatment of cGvHD. Calcineurin inhibitors may be useful in initial treatment and as steroid-sparing agents.

Monitor the response to this initial treatment. If response is not adequate there are a range of other treatment available. None of these are very effective and some are not readily available in New Zealand.

2nd line and beyond therapy of chronic GvHD

General principles

The “trial and error” system remains the commonest approach because no predictors of response exist. General principles adopted are:

BCSH guidelines recommendations:

Results of an EBMT survey on 1st and 2nd line therapy of chronic GvHD

Notes:

About this Canterbury DHB document (9081):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

December 2016

Next Review:

December 2018

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 9081